PCOD, PCOS, Now PMOS…Why the Name Change Is Bigger Than You Think

If you have been diagnosed with PCOD or PCOS — or know someone who has — you may have seen the news this month. The condition has a new name. On May 12, 2026, a global panel of 56 leading clinical and patient organisations published a landmark paper in The Lancet officially renaming it. What was Polycystic Ovary Syndrome is now Polyendocrine Metabolic Ovarian Syndrome — PMOS.

Eleven years of research. Over 22,000 survey responses from patients and clinicians across six continents. One letter changed in the acronym. And the difference is enormous.

Walking through the names

The condition has had three names, and each one tells you something about how medicine's understanding of it evolved.

It started as PCOD — Polycystic Ovarian Disease. Polycystic means many cysts, ovarian means it lives in the ovaries, and disease means something is broken there. This is the term still widely used in everyday conversation in India — and it planted the idea, early on, that this was essentially an ovarian problem involving cysts.

It became PCOS — Polycystic Ovary Syndrome. The shift from disease to syndrome was a small improvement — a syndrome acknowledges a cluster of features rather than one broken organ. But the name still pointed squarely at the ovaries, and still led with cysts.

Now it is PMOS — Polyendocrine Metabolic Ovarian Syndrome. Break it down simply: poly means multiple, endocrine means hormonal, metabolic means how the body handles energy and blood sugar, ovarian means the ovaries are involved, and syndrome means it shows up differently in different people. Together, the name is saying: this is a whole-body hormonal and metabolic condition — not an ovarian disease, not about cysts.

The problem with the old name

Here is the central issue: the "cysts" in polycystic ovary syndrome are not actually cysts. They are arrested follicles — small, immature egg sacs that did not fully develop. Many women with PCOS have none visible on ultrasound at all. Many women without the condition do have them.

This single misrepresentation caused real harm. Women were told their ovaries were covered in cysts. Some underwent unnecessary procedures. Others were told they did not have the condition because no cysts showed up on their scan — and went undiagnosed for years. Up to 70 percent of people with the condition were never diagnosed at all.

Meanwhile, the actual driver of the condition — insulin resistance — was being addressed incompletely or not at all, because the name had everyone looking at the wrong place.

What PMOS actually is

At its core, PMOS is a condition of insulin resistance. The body's cells stop responding properly to insulin, which triggers a hormonal cascade: excess insulin stimulates the ovaries to overproduce androgens — male hormones — which disrupt ovulation, cause irregular periods, drive acne, cause hair thinning on the scalp and growth on the face, and contribute to weight gain around the abdomen.

The ovaries are caught in this cascade. They are not its origin. That is the shift the new name is making.

Why renaming it matters beyond semantics

It changes what gets tested. The 2026 diagnostic update now formally includes metabolic markers — fasting insulin, HbA1c, and visceral fat assessment — alongside the older criteria of irregular periods and ultrasound findings. Clinicians are now expected to assess the full metabolic picture, not just look for follicles on a scan.

It changes the treatment conversation. For years, the most common treatment offered in India was an oral contraceptive to regulate periods, and an ovulation drug when pregnancy was the goal. Both are valid. But neither addresses the insulin resistance sitting underneath. The new framing explicitly shifts treatment toward targeting that root cause — through lifestyle change, metformin, and newer metabolic medications — rather than managing symptoms alone.

It reduces stigma. Naming the condition after ovarian cysts made it sound like a reproductive problem — something to deal with when fertility became a concern and ignore otherwise. Framing it as a serious metabolic and endocrine disorder changes the clinical respect it receives and the urgency with which it is managed.

It opens new research directions. PMOS presents very differently in different women — one person's primary burden is fertility, another's is insulin resistance and diabetes risk, another's is mental health. A name that reflects the full condition allows research and personalised treatment to follow the actual biology.

Why this matters especially in India

An estimated 44 million Indian women are affected. Prevalence studies put the rate between 16 and 22 percent of women of reproductive age — significantly higher than global averages. And Indian women develop metabolic complications at younger ages and lower BMI thresholds than Western populations, making early identification of insulin resistance and cardiometabolic risk particularly important.

Many Indian women have been missed precisely because they had no visible cysts. The move toward metabolic and hormonal markers changes that.

What stays the same

Your diagnosis does not need to change. The biology has not changed. Both names will be in circulation through a planned three-year transition. What has changed is how medicine is being asked to think about the condition — and that shift, over time, will change what gets tested, what gets treated, and how seriously it gets taken from the first appointment.

PCOS was named after what doctors could see on an ultrasound. PMOS is named after what is actually happening in the body. That is what eleven years of global work and one carefully chosen letter amounts to.

If you have a PCOD or PCOS diagnosis and feel your treatment has focused mainly on periods and fertility without addressing the metabolic picture — insulin resistance, weight, blood sugar — that is a conversation worth raising at your next visit.